Back to top
more

Coherus BioSciences (CHRS)

(Delayed Data from NSDQ)

$2.04 USD

2.04
907,173

+0.11 (5.70%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $2.04 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for CHRS

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Coherus BioSciences, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 118 192 417 541 178
Receivables 261 110 123 0 142
Notes Receivable 0 0 0 157 0
Inventories 63 39 38 44 10
Other Current Assets 35 41 24 25 14
Total Current Assets 476 381 602 767 343
Net Property & Equipment 5 9 8 10 6
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 68 76 56 48 45
Deferred Charges 0 0 0 0 0
Intangibles 72 6 4 4 4
Deposits & Other Assets 10 9 10 3 1
Total Assets 630 481 679 842 409
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 35 12 16 15 26
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 297 127 149 127 87
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 0 0 4 2
Total Current Liabilities 332 139 165 146 115
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 227 226 333 330 105
Long-Term Debt 246 245 76 74 74
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 13 3 1 1 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 823 618 582 561 304
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 1,386 1,204 1,148 1,044 1,001
Retained Earnings -1,580 -1,342 -1,050 -763 -895
Other Equity 0 0 0 0 -1
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity -193 -137 98 281 105
Total Liabilities & Shareholder's Equity 630 481 679 842 409
Total Common Equity -193 -137 98 281 105
Shares Outstanding 111.30 77.70 76.70 72.00 70.10
Book Value Per Share -1.74 -1.77 1.27 3.90 1.50

Fiscal Year End for Coherus BioSciences, Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 118 131 145 128
Receivables NA 261 217 141 101
Notes Receivable NA 0 0 0 0
Inventories NA 63 67 64 49
Other Current Assets NA 35 30 35 37
Total Current Assets NA 476 444 385 316
Net Property & Equipment NA 5 6 7 8
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 68 79 64 65
Deferred Charges NA 0 0 0 0
Intangibles NA 72 47 6 6
Deposits & Other Assets NA 10 8 8 8
Total Assets NA 630 584 470 402
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 35 37 29 23
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 297 203 140 100
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 0 0 0 0
Total Current Liabilities NA 332 240 169 123
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 0 0
Convertible Debt NA 227 227 226 226
Long-Term Debt NA 246 246 246 246
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 4 0 0
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 823 717 644 599
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 1,386 1,367 1,286 1,221
Retained Earnings NA -1,580 -1,500 -1,460 -1,417
Other Equity NA 0 0 0 0
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA -193 -134 -175 -197
Total Liabilities & Shareholder's Equity NA 630 584 470 402
Total Common Equity 0 -193 -134 -175 -197
Shares Outstanding 112.70 111.30 94.40 80.50 80.50
Book Value Per Share 0.00 -1.74 -1.42 -2.17 -2.44